Pharmafile Logo
T40 2022 Cover
Diversity, Equity and Inclusion
Communiqué 53 Cover Image
- PMLiVE

inotuzumab ozogamicin

- PMLiVE

Pfizer warns that IP waiver for COVID-19 vaccines may invite ‘copycat medicines’

Company says removing IP protections would make it ‘harder’ to make vaccines in the short term

- PMLiVE

Emergency authorisation for Pfizer/BioNTech vaccine expanded in the US

Data from a study involving 12 to 15 year olds has also been submitted to the EMA for potential approval

- PMLiVE

Pfizer, BioNTech file for full US approval of COVID-19 vaccine

Pfizer chief executive Albert Bourla said last week the company is on track to supply 2.7bn doses in 2021

- PMLiVE

Pfizer pauses enrolment for trial evaluating anti-BCMA bispecific antibody

Trial pause follows reports of three cases of peripheral neuropathy in phase 1 study

- PMLiVE

BioNTech on course to produce three billion doses of Pfizer-partnered COVID-19 vaccine in 2021

BioNTech’s CEO Ugur Sahin said increase in manufacturing will allow for this target to be met

- PMLiVE

Pfizer’s COVID-19 vaccine yields $3.5bn in first quarter sales

Full-year guidance for BioNTech-partnered vaccine increased to $26bn

- PMLiVE

Pfizer acquires Amplyx Pharmaceuticals, including new potential class of therapeutics

Drug could treat life-threatening antifungal-resistant infections

- PMLiVE

Pfizer CEO says oral COVID-19 pill could be ready by the end of the year

Company initiated a phase 1 study of the drug last month

- PMLiVE

NICE sets out plans for ‘ambitious’ five-year strategy

NICE refocuses on reducing health inequalities and accelerating access to the latest and most effective treatments

- PMLiVE

Alexion and NICE agree confidential discount for Ultomiris use on the NHS

NICE said clinical evidence shows Ultomiris is as effective and safe as Alexion's older PNH drug Soliris

- PMLiVE

Pfizer/BioNTech’s COVID-19 vaccine is 100% effective in adolescents

Vaccine was found to be safe and effective in adolescents aged 12 to 15 years old

- PMLiVE

BioNTech forecasts €9.8bn in sales of Pfizer-partnered COVID-19 vaccine in 2021

Company also raised full year manufacturing capacity target for vaccine to 2.5 billion doses

Subscribe to our email news alerts

Latest jobs from #PharmaRole

Latest content

Latest intelligence

Quick links